Bausch + Lomb Corporation ( (BLCO) ) has released its Q3 earnings. Here is a breakdown of the information Bausch + Lomb Corporation presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bausch + Lomb Corporation is a leading global eye health company, operating in the vision care, pharmaceuticals, and surgical segments, dedicated to enhancing vision care worldwide. In its latest earnings report for the quarter ending September 30, 2025, Bausch + Lomb reported a slight increase in revenues compared to the previous year, with product sales reaching $1.277 billion. However, the company experienced a net loss of $28 million for the quarter, attributed to increased costs and expenses. Key financial metrics showed a rise in operating income to $95 million, despite a significant interest expense of $101 million. Looking ahead, Bausch + Lomb’s management remains focused on strategic initiatives and operational efficiencies to navigate economic challenges and enhance shareholder value.